Brief: Urogen Initiates Submission Of A Rolling NDA To The FDA For Ugn-102
24/01/2024 15:34
Jan 24 (Reuters) - Urogen Pharma Ltd UR8.F :
* UROGEN INITIATES SUBMISSION OF A ROLLING NDA TO THE FDA
FOR
UGN-102
* UROGEN PHARMA LTD: POTENTIAL FDA DECISION AS EARLY AS Q1
OF 2025
Source text for Eikon: ID:nBw29MRM8a
Further company coverage: UR8.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors